Geron Corp. (GERN) and GE Healthcare, a unit of General Electric Co. (GE), announced Tuesday morning that they entered into a global exclusive license and alliance agreement to develop and commercialize cellular assay products derived from human embryonic stem cells for use in drug discovery, development and toxicity screening.
Geron Corp. gapped up sharply Tuesday and has continued to rise gradually on the highest volume in over a month. The stock is now challenging resistance at the highs of the year, trading at nearly a 5-month high.
For comments and feedback: editorial@rttnews.com